embalaje : 10mg
Synonyms: L-Epicatechin, Epicatechin, (-)-Epicatechol
| Description | (-)-Epicatechin (Epicatechin) belongs to natural products and is a COX-1 inhibitor (IC50 = 3.2 μM) with cell permeability. By blocking the nuclear localization of the p65 subunit of NF-κB, this compound inhibits IL-1β-induced iNOS expression and possesses significant anti-inflammatory activity. |
| Targets & IC50 | COX-1:3.2 μM, MDA-MB-231 cells:85 μM |
| In vitro | Method: Panc-1, U87, and MIA PaCa-2 cancer cells as well as normal human fibroblasts were treated with (-)-epicatechin to detect mitochondrial respiration, oxygen consumption, radiation sensitivity under combined irradiation, and levels of Chk2 phosphorylation and p21 induction. Result: (-)-Epicatechin stimulated mitochondrial respiration and oxygen consumption only in Panc-1 cells; selectively enhanced radiation sensitivity in cancer cells (REF 1.7, 1.5, and 1.2 for Panc-1, U87, and MIA PaCa-2, respectively) without enhancement in normal fibroblasts (REF = 0.9); and increased Chk2 phosphorylation and p21 induction only in cancer cells when combined with irradiation.[1] |
| In vivo | Method: 26-month-old C57BL/6 aged mice were administered (-)-epicatechin (1 mg/kg, twice daily) by gavage for 2 weeks (vehicle: water). Additionally, 6 middle-aged subjects (41 ± 5 years) were given (-)-epicatechin capsules (25 mg, twice daily) for 7 days. Muscle regulatory factors and hand grip strength were measured. Result: (-)-Epicatechin reduced elevated myostatin and β-galactosidase, and increased follistatin and Myf5 in aged mice; in humans, it increased hand grip strength (~7%) and plasma follistatin/myostatin ratio, reversing aging-related changes.[2] Method: 5-month-old C57BL/6 male mice were randomly divided into control group, training group, detraining + placebo (water) group, and detraining + (-)-epicatechin (1 mg/kg, gavage, twice daily) group. Skeletal muscle capillary density, VEGF-A/TSP-1 expression, oxidative enzyme activity, and endurance were measured. Result: Compared with the placebo group, (-)-epicatechin significantly increased skeletal muscle capillary density and oxidative enzyme activity in detrained mice, maintained mitochondrial complex IV and cytochrome c oxidase activity, reduced the decline in VEGF-A/TSP-1 ratio, and preserved endurance comparable to the training group.[3] |
| Synonyms | L-Epicatechin, Epicatechin, (-)-Epicatechol |
| Cell Research | Panc-1 cells are seeded into T-150 flasks and on the next day, cells are treated with different concentrations of (-)-epicatechin for 1 h, then harvested and solubilized in 10 mM HEPES (pH 7.4), 40 mM KCl, 1%Tween-20, 1 μM oligomycin, 1 mM PMSF,10 mM KF, 2 mM EGTA, and 1 mM Na3VO4. COX activity is measured in the presence of 20 mM ascorbate and 200 μM substrate cytochrome c from cow heart.(Only for Reference) |
| Molecular Weight | 290.27 |
| Formula | C15H14O6 |
| Cas No. | 490-46-0 |
| Smiles | O[C@H]1[C@@H](C2=CC=C(O)C(O)=C2)OC3=C(C(O)=CC(O)=C3)C1 |
| Relative Density. | 1.593g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: 2.25 mg/mL (7.75 mM), Sonication is recommended.  DMSO: 80.00 mg/mL (275.61 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 50% PEG300+50% Saline: 5.00 mg/mL (17.23 mM) 0.5% CMC-Na: 5.00 mg/mL (17.23 mM), Sonication is recommended. 10% DMSO+90% Saline: 10.00 mg/mL (34.45 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
